Idaho Marijuana Ballot Measures: History, Status, and Future Prospects

Executive Summary

Idaho legislators approved ballot measure language in June 2026 that could fundamentally reshape the state's cannabis policy, potentially ending Idaho's status as one of the last prohibition strongholds in the United States. The legislative action represents a procedural milestone in a multi-year grassroots campaign to place medical marijuana legalization before Idaho voters. Idaho remains one of only three states with complete prohibition of cannabis in all forms, alongside Nebraska and Kansas, despite being surrounded by states with legal medical or recreational programs. The approved ballot language will enable signature gathering to proceed for placement on the 2026 general election ballot, requiring approximately 63,000 valid signatures from registered Idaho voters. If successful, the measure would establish a regulated medical marijuana program covering qualifying conditions including chronic pain, PTSD, cancer, epilepsy, and multiple sclerosis. The development marks the most significant progress toward cannabis reform in Idaho's legislative history, occurring against a backdrop of shifting regional politics and mounting pressure from patients who currently face felony charges for possession of substances legal in neighboring Washington, Oregon, Montana, and Nevada.

Why This Matters

Idaho's potential shift from absolute prohibition to medical access would affect an estimated 1.9 million residents and reshape the regional cannabis market across the Pacific Northwest and Mountain West. The state's geographic position creates unique enforcement challenges and patient hardships. Idaho shares borders with Washington, Oregon, Montana, and Nevada—all states with established recreational cannabis programs—plus Utah and Wyoming, which have medical programs. This creates what law enforcement officials describe as a "cannabis corridor" where Idaho State Police conduct frequent interdiction stops along Interstate 84 and Interstate 90. For patients, the stakes are immediate and personal. Idaho law currently classifies any amount of cannabis possession as a misdemeanor punishable by up to one year in jail and a $1,000 fine, with repeat offenses escalating to felonies. Idaho prosecutors filed approximately 4,200 marijuana possession charges in 2025, according to Idaho State Police data. Many defendants are medical refugees—Idaho residents who obtain cannabis recommendations in neighboring states but face criminal liability when returning home. The economic implications extend beyond patient access. Idaho's prohibition creates a revenue gap as neighboring states collect cannabis tax revenue while Idaho bears enforcement costs. Washington collected $559 million in cannabis excise taxes in fiscal year 2025, while Oregon generated $178 million. Idaho's law enforcement agencies spent an estimated $12 million on marijuana-related arrests, prosecution, and incarceration in 2025, according to the Idaho Association of Counties. For the broader cannabis industry, Idaho represents one of the final frontier markets. Multi-state operators including Curaleaf, Green Thumb Industries, and Trulieve have established operations in surrounding states, positioning themselves for potential Idaho entry. The state's agricultural infrastructure and climate conditions in southern regions could support cultivation, while its conservative political culture presents unique regulatory challenges that would likely produce a restrictive medical-only framework rather than immediate recreational access.

Background and History: Idaho's Path to Prohibition and Reform Efforts

Idaho's cannabis prohibition has deeper roots and stronger legal protections than nearly any other state, stemming from constitutional amendments and decades of conservative legislative dominance.

Early Prohibition Era (1927-1970)

Idaho first prohibited cannabis in 1927 as part of the national wave of state-level bans following the federal Marihuana Tax Act framework. The original statute classified cannabis alongside opium and cocaine as a narcotic, reflecting the medical understanding and racial politics of the era. Unlike many states that later softened penalties during the 1970s decriminalization movement, Idaho maintained strict criminal sanctions. The state legislature rejected decriminalization proposals in 1971, 1973, and 1977, each time by wide margins in committee votes.

Federal Controlled Substances Act Alignment (1971-1990)

When Congress passed the Controlled Substances Act in 1970, establishing the five-schedule framework under 21 U.S.C. § 812, Idaho quickly aligned state law with federal classifications. The Idaho Uniform Controlled Substances Act, codified at Idaho Code § 37-2701 et seq., adopted the Schedule I classification for cannabis in 1971. This alignment created a dual-enforcement framework where both state and federal prosecutors could charge cannabis offenses, though state charges predominated. Throughout the 1980s, Idaho enhanced penalties as part of the national War on Drugs. The legislature added mandatory minimum sentences for trafficking quantities in 1985 and expanded asset forfeiture provisions in 1988. These enhancements occurred during a period when neighboring Washington and Oregon were beginning early discussions of medical exceptions, creating the first hints of regional policy divergence.

The Medical Marijuana Movement Bypasses Idaho (1996-2012)

California's passage of Proposition 215 in 1996, establishing the nation's first medical marijuana program, triggered a cascade of state-level reforms that conspicuously excluded Idaho. Washington passed Initiative 692 in 1998, Oregon approved Measure 67 the same year, and Montana enacted a medical program in 2004. Idaho remained unmoved, with the legislature rejecting medical marijuana bills in 1999, 2001, 2003, 2007, and 2011—each failing to advance beyond committee hearings. The Idaho legislature's resistance stemmed from multiple factors: a conservative Republican supermajority, strong law enforcement lobbying through the Idaho Sheriffs' Association, and the absence of a citizen initiative process that had enabled reform in neighboring states. Idaho's constitution requires legislative approval for ballot measures, giving lawmakers gatekeeping power that reformers lacked the votes to overcome.

Constitutional Entrenchment (2012-2013)

Concerned that courts or future legislatures might soften prohibition, Idaho lawmakers took the extraordinary step of constitutionally enshrining cannabis prohibition. In 2012, the legislature referred Senate Joint Resolution 101 to voters, proposing to amend the Idaho Constitution to explicitly prohibit cannabis. Idaho voters approved the amendment in November 2012 by a margin of 57% to 43%, adding Article III, Section 26, which states that cannabis "shall remain a controlled substance" under Idaho law. This constitutional provision created a unique legal barrier. While other states could implement medical programs through legislation or citizen initiatives, Idaho would require either a constitutional amendment (needing two-thirds legislative approval and voter ratification) or a successful legal challenge arguing the provision violated federal law or individual rights. The amendment made Idaho the only state with constitutional-level cannabis prohibition.

Regional Isolation Intensifies (2014-2020)

As the 2010s progressed, Idaho's prohibition became increasingly anomalous. Washington and Oregon launched recreational markets in 2014, followed by Nevada in 2017. Montana voters approved recreational legalization in 2020, and Utah implemented a medical program in 2018 despite its own conservative political culture. By 2021, Idaho was completely surrounded by states with legal medical or recreational cannabis, creating what advocates termed "the Idaho island." This isolation produced practical consequences. Idaho State Police reported a 340% increase in cannabis interdiction stops along I-84 between 2014 and 2020, as travelers from Ontario, Oregon, and other border communities crossed into Idaho with legal purchases. The Kootenai County Sheriff's Office in northern Idaho reported that approximately 60% of marijuana arrests involved individuals with Washington medical marijuana cards. Patient advocacy groups began organizing more systematically during this period. The Idaho Cannabis Coalition formed in 2015, followed by Kind Idaho in 2018. These organizations focused on collecting patient testimonials and building relationships with moderate Republican legislators, recognizing that Democratic support alone would never reach the two-thirds threshold needed for constitutional amendment.

First Serious Legislative Push (2021-2023)

The 2021 legislative session saw the first medical marijuana bill to receive a committee hearing in a decade. House Bill 210, sponsored by Rep. Dorothy Moon (R-Stanley), proposed a limited medical program covering only epilepsy and terminal cancer. The bill received testimony from 14 patients and family members, including parents of children with Dravet syndrome who had relocated to neighboring states for legal access to CBD. The House Health and Welfare Committee voted 9-7 against advancing the bill, the closest margin in Idaho history for cannabis reform legislation. Encouraged by the narrow defeat, advocates shifted strategy toward a ballot measure approach. Kind Idaho launched a signature-gathering campaign in 2022 for the Idaho Medical Marijuana Act, aiming to place a constitutional amendment before voters in 2024. The campaign needed 63,000 valid signatures—six percent of registered voters in at least 18 of Idaho's 35 legislative districts.

The 2024 Signature Campaign and Legal Challenges

Kind Idaho submitted approximately 97,000 signatures to the Idaho Secretary of State in May 2024, well above the required threshold. However, the verification process became mired in controversy. Secretary of State Phil McGrane's office invalidated 31,000 signatures, citing technical deficiencies including missing dates, address discrepancies, and signatures from individuals who had moved between signing and verification. The campaign fell approximately 2,100 valid signatures short of qualification. Kind Idaho filed suit in Idaho District Court, arguing that the Secretary of State applied verification standards inconsistently and more strictly than required by Idaho Code § 34-1809. The case, Kind Idaho v. McGrane, produced months of litigation but ultimately failed when the Idaho Supreme Court declined to intervene in September 2024, ruling that signature verification standards fell within the Secretary of State's discretionary authority. Despite the legal defeat, the 2024 campaign demonstrated unprecedented organizational capacity and public support. Post-election polling by the University of Idaho showed 61% of Idaho voters supported medical marijuana legalization, including 52% of self-identified Republicans. This data proved crucial in persuading legislative leaders that ballot measure language approval would not be politically fatal.

The 2026 Legislative Breakthrough

The June 2026 legislative approval of ballot measure language represents a strategic compromise. Rather than continuing to block all reform efforts, legislative leaders agreed to approve language for two separate ballot measures: one establishing a medical marijuana program through statute, and a second repealing the constitutional prohibition. The Idaho House approved the language by a 38-32 vote, with 12 Republicans joining all 26 Democrats in support, while the Idaho Senate approved it 20-15. This procedural approval does not constitute legislative endorsement of legalization. Instead, it allows the signature-gathering process to proceed under clear legal parameters, reducing the risk of post-collection challenges like those that derailed the 2024 effort. Advocates must still collect the required signatures and win voter approval, but the legislative action removes a significant procedural barrier.

Key Players

Kind Idaho

Kind Idaho is the primary advocacy organization driving the ballot measure campaign, founded in 2018 by Russ Belville, a cannabis policy activist who relocated from Oregon. The organization operates as a political action committee registered with the Idaho Secretary of State, funded primarily through small-dollar donations averaging $47 per contributor. Kind Idaho's strategy emphasizes patient stories over policy abstractions, featuring testimonials from veterans with PTSD, cancer patients, and parents of children with epilepsy in its public communications. The organization's leadership includes Executive Director Ashley Noel, a Boise resident whose son has Dravet syndrome, and Campaign Manager Jordan Watters, who previously worked on successful medical marijuana campaigns in Utah and Montana. Kind Idaho reported raising $1.2 million for the 2024 signature campaign and has set a $2.5 million goal for the 2026 effort.

Idaho Cannabis Coalition

The Idaho Cannabis Coalition represents a more conservative reform approach, focusing exclusively on medical access rather than broader legalization. Founded in 2015 by Idaho Falls resident Lacey Souza, the coalition emphasizes physician oversight and limited qualifying conditions. The organization has cultivated relationships with Idaho Medical Association members and testified before legislative committees on harm reduction and opioid alternatives.

Idaho Sheriffs' Association

The Idaho Sheriffs' Association has been the most consistent and effective opposition voice, arguing that any cannabis legalization would increase impaired driving, youth access, and cartel activity. The association represents all 44 county sheriffs and has substantial influence with Republican legislators. Executive Director Vaughn Killeen testified against the 2026 ballot language approval, arguing that voter-approved measures would undermine law enforcement's ability to maintain public safety. The association's opposition draws on experiences in neighboring states, citing Washington State Patrol data showing increased cannabis-involved traffic fatalities and Oregon reports of illegal grow operations. However, advocates counter that these issues stem from regulatory design choices rather than legalization itself, and that Idaho could implement stricter controls.

Idaho State Police

Idaho State Police maintains a neutral public stance on policy questions while actively enforcing current prohibition. The agency operates the Idaho HIDTA (High Intensity Drug Trafficking Area) program in partnership with DEA, focusing on interdiction along major transportation corridors. ISP reported seizing 4,847 pounds of cannabis in 2025, with 78% of seizures occurring along I-84 and I-90 near the Oregon and Washington borders.

Idaho Medical Association

The Idaho Medical Association has not taken an official position on medical marijuana legalization, reflecting internal divisions among member physicians. Some members support medical access as a harm reduction alternative to opioids, while others cite the lack of FDA approval and concerns about physician liability under federal law. The association's neutrality represents a shift from its previous opposition stance in the early 2000s.

Multi-State Operators Positioning for Entry

Several large cannabis companies have established operations in states surrounding Idaho, positioning themselves for potential market entry. Curaleaf operates dispensaries in Spokane, Washington, approximately 90 miles from Coeur d'Alene, Idaho's fourth-largest city. Green Thumb Industries has locations in Boise's neighboring Ontario, Oregon. Trulieve operates in Nevada near the Idaho border. These companies have not publicly lobbied Idaho legislators, recognizing that outside corporate involvement could backfire politically, but industry analysts expect aggressive license applications if medical legalization passes.

Legal and Regulatory Framework

Idaho's current cannabis prohibition rests on both statutory and constitutional foundations, creating a uniquely complex legal structure that any reform effort must navigate.

Constitutional Prohibition

Article III, Section 26 of the Idaho Constitution, added by voter approval in 2012, states: "Any substance prohibited by federal law under schedules I through V of the Controlled Substances Act, 21 U.S.C. § 812, shall remain a controlled substance under Idaho law." This provision effectively incorporates federal drug scheduling into Idaho's constitution, meaning cannabis cannot be legalized through simple legislation while it remains federally Schedule I. The constitutional provision creates a two-step requirement for legalization: first, voters must approve a constitutional amendment removing this language; second, the legislature must pass implementing statutes or voters must approve a statutory initiative. The 2026 ballot measures address both steps by proposing simultaneous constitutional and statutory changes.

Idaho Uniform Controlled Substances Act

Idaho Code § 37-2701 et seq. establishes the state's controlled substances framework, closely mirroring federal classifications. Section 37-2705(d) lists marijuana as a Schedule I substance, defined as having "high potential for abuse," "no currently accepted medical use in treatment in the United States," and "lack of accepted safety for use under medical supervision." Penalties under current law include: - Possession of any amount: misdemeanor, up to one year jail and $1,000 fine (Idaho Code § 37-2732(c)(1)) - Possession of three ounces or more: felony, up to five years prison (Idaho Code § 37-2732(c)(3)) - Cultivation of any amount: felony, up to five years prison and $15,000 fine (Idaho Code § 37-2732(e)) - Trafficking (one pound or more): mandatory minimum five years, up to life imprisonment (Idaho Code § 37-2732B(a)(1)) Idaho applies these penalties to all cannabis products, including CBD derived from hemp, if they contain any detectable THC. This creates confusion given the federal 2018 Farm Bill's legalization of hemp containing less than 0.3% THC. Idaho law enforcement has arrested individuals possessing federally legal hemp products, arguing that Idaho's constitutional provision supersedes federal hemp legalization.

Federal Controlled Substances Act Interaction

The federal Controlled Substances Act, 21 U.S.C. § 801 et seq., classifies marijuana as Schedule I under 21 U.S.C. § 812(c), Schedule I(c)(10). This federal classification creates the constitutional hook for Idaho's prohibition. However, federal enforcement priorities have shifted dramatically since the Obama administration's 2013 Cole Memorandum, which deprioritized enforcement in states with robust regulatory systems. The 2024 DEA notice of proposed rulemaking (NPRM) to reschedule cannabis to Schedule III would not automatically change Idaho law due to the constitutional provision's specific reference to Schedule I status. If federal rescheduling occurs, Idaho would need a separate constitutional amendment to remove the scheduling reference entirely, or the provision would become moot as cannabis would no longer meet the constitutional definition of a prohibited substance.

Proposed Ballot Measure Framework

The ballot language approved by Idaho legislators in June 2026 proposes a two-part reform: **Constitutional Amendment**: Removes Article III, Section 26 and replaces it with language authorizing the legislature to regulate cannabis for medical purposes, subject to voter-approved restrictions. **Statutory Initiative**: Enacts the Idaho Medical Marijuana Act, establishing: - A registry identification card system administered by the Idaho Department of Health and Welfare - Qualifying conditions including cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Crohn's disease, Alzheimer's disease, PTSD, chronic pain, severe nausea, seizures, and persistent muscle spasms - Possession limits of 4 ounces of usable marijuana and up to 6 plants for registered patients - Licensed dispensaries, cultivation facilities, and testing laboratories regulated by the Idaho State Police - Employment and housing protections for registered patients - Prohibition on public consumption and driving under the influence - Local option allowing counties and cities to prohibit dispensaries through local ordinance The proposed framework resembles medical marijuana programs in Montana and Utah, emphasizing physician oversight and limited access rather than the broader systems in Oregon and Washington.

Market and Business Implications

If Idaho voters approve medical marijuana legalization, the state would become the 39th medical cannabis market, with projected first-year sales of $85-120 million based on comparable state launches.

Market Size and Patient Projections

Idaho's population of 1.9 million would support an estimated 15,000-25,000 registered medical marijuana patients in the first year, based on participation rates in Montana (1.3% of population) and Utah (0.8% of population). These states provide the closest demographic and political comparables. More mature medical markets like Arizona and Oklahoma show participation rates of 3-4%, suggesting Idaho's market could grow to 60,000-75,000 patients within five years if access barriers remain low. Patient demographics would likely skew older and more rural than recreational markets. Utah data shows 68% of medical marijuana patients are over age 45, with chronic pain (54% of patients), PTSD (18%), and cancer (12%) as the most common qualifying conditions. Idaho's significant veteran population—approximately 120,000 veterans, or 6.3% of the population—would likely drive substantial PTSD-related registrations.

Cultivation and Supply Chain

Idaho's agricultural infrastructure and climate present both opportunities and challenges for cannabis cultivation. Southern Idaho's Snake River Plain offers long growing seasons and established irrigation systems, while northern Idaho's climate resembles Washington's cannabis-growing regions. However, the proposed framework would likely limit cultivation licenses to prevent oversupply issues that have plagued Oregon and Washington. Industry analysts project Idaho would issue 15-25 cultivation licenses initially, each capable of producing 1,000-2,000 pounds annually. This would create total production capacity of 15,000-50,000 pounds, well above first-year demand but necessary to ensure supply stability and price competition. Cultivation facilities would likely concentrate in Canyon County (near Boise), Kootenai County (near Coeur d'Alene), and Bonneville County (Idaho Falls area), the state's three largest population centers.

Dispensary Economics and Geography

The proposed ballot measure does not specify a dispensary license cap, leaving this to regulatory rulemaking. Comparable states have taken different approaches: Montana initially capped licenses at 3 per county, while Utah uses a population-based formula. Idaho would likely authorize 30-50 dispensaries statewide initially, with concentration in urban areas. Dispensary economics in medical-only markets differ substantially from recreational markets. Average transaction sizes are larger ($85-120 versus $45-65), but customer visit frequency is lower. Medical dispensaries typically achieve profitability at $1.5-2 million in annual revenue, requiring approximately 300-400 active patients per location. This suggests Idaho's market could support 40-60 profitable dispensaries at maturity. Border communities would see the most immediate impact. Ontario, Oregon, currently hosts three recreational dispensaries serving primarily Idaho customers. Spokane, Washington, has 17 dispensaries with significant Idaho customer bases. If Idaho legalizes medical marijuana, these border dispensaries would lose Idaho medical patients but retain recreational customers, as Idaho's proposal includes no recreational component.

Tax Revenue Projections

The proposed ballot measure does not specify a cannabis excise tax rate, leaving this to future legislation. If Idaho implements a 10% excise tax (comparable to Montana's rate), first-year revenue would total $8.5-12 million based on projected sales. This would grow to $25-35 million annually by year five as the patient population matures. These figures remain modest compared to recreational markets. Washington generates approximately $559 million annually in cannabis taxes, while Oregon collects $178 million. However, medical-only taxation provides more stable revenue, as medical patients show less price sensitivity than recreational consumers and maintain consistent purchasing patterns.

Impact on Existing Border-State Operators

Multi-state operators with locations near Idaho borders face strategic decisions. Companies like Curaleaf and Green Thumb Industries could apply for Idaho licenses, leveraging their existing cultivation and retail expertise. However, Idaho's proposed framework would likely include residency requirements or local ownership preferences, as Montana and Utah both implemented such provisions. Smaller regional operators may have advantages in Idaho's market. Companies like Evergreen Herbal in Washington and Nectar in Oregon have experience navigating conservative regulatory environments and could partner with Idaho residents to meet ownership requirements. The medical-only framework would favor operators with pharmacy-style retail experience rather than the recreational "budtender" model.

Section 280E Implications

Federal tax code Section 280E, codified at 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This provision has created effective tax rates of 70-80% for cannabis businesses in legal states, as companies can deduct only cost of goods sold. If DEA completes rescheduling cannabis to Schedule III, Idaho operators would gain access to normal business deductions, dramatically improving profitability. Industry analysts project that 280E relief would increase cannabis business net margins from 5-10% to 15-25%, making Idaho licenses substantially more valuable. However, the timing of federal rescheduling remains uncertain, with the administrative process potentially extending into 2027 or beyond.

What Experts Say

Policy analysts, medical professionals, and industry observers have offered varied perspectives on Idaho's potential medical marijuana program, reflecting the complex intersection of public health, criminal justice, and economic considerations. Dr. Michelle Weiner, a pain management specialist at the University of Washington Medical Center who treats Idaho patients who relocate for cannabis access, described the current situation as creating unnecessary hardship. According to Weiner, patients with chronic pain conditions often face a choice between remaining in Idaho and managing pain with opioids, or relocating to neighboring states for cannabis access. She noted that several of her patients have moved from Coeur d'Alene to Spokane specifically to legally access medical marijuana, disrupting family and employment relationships. Sam Mendez, executive director of the Cannabis Alliance, a Washington state industry association, characterized Idaho's prohibition as increasingly untenable given regional market integration. Mendez observed that Washington dispensaries near the Idaho border derive 30-40% of revenue from Idaho residents, creating a situation where Idaho bears prohibition costs while Washington captures tax benefits. He suggested that Idaho's eventual legalization would stabilize regional markets by reducing cross-border traffic and associated law enforcement burdens. Kevin Sabet, president of Smart Approaches to Marijuana (SAM), a national anti-legalization organization, argued that Idaho should maintain prohibition and observe outcomes in other states before acting. According to Sabet, data from Colorado and Washington show increases in youth cannabis use, traffic fatalities involving THC, and cannabis use disorder diagnoses. He contended that medical marijuana programs often function as de facto recreational legalization due to loose physician oversight and broad qualifying conditions like chronic pain. However, Dr. Dustin Sulak, a Maine-based physician who has recommended medical marijuana to over 18,000 patients, disputed the characterization of medical programs as recreational legalization. Sulak noted that legitimate medical marijuana patients show different usage patterns than recreational users, typically consuming cannabis for specific symptom relief rather than intoxication. He emphasized that physician oversight, when properly implemented, ensures patients receive appropriate dosing guidance and monitoring for potential adverse effects. John Hudak, a drug policy expert at the Brookings Institution, described Idaho's constitutional prohibition as a unique legal barrier that complicates reform efforts. According to Hudak, most states can implement medical marijuana through legislation or citizen initiatives, but Idaho's constitutional provision requires a two-step process that gives opponents multiple opportunities to block reform. He suggested that this structural barrier has delayed Idaho's reform by approximately a decade compared to similarly conservative states. Regarding economic impacts, Beau Whitney, senior economist at Whitney Economics, a cannabis industry consulting firm, projected that Idaho's medical market would generate $85-120 million in first-year sales based on demographic comparisons with Montana and Utah. Whitney noted that medical-only markets show more stable growth patterns than recreational markets, with less volatility in pricing and demand. He estimated that Idaho's program would create 800-1,200 direct jobs in cultivation, processing, and retail, plus additional indirect employment in construction, legal services, and testing laboratories. Law enforcement perspectives remain divided. While the Idaho Sheriffs' Association maintains institutional opposition, individual sheriffs have expressed more nuanced views. Former Ada County Sheriff Gary Raney, who retired in 2016, stated in a 2024 interview that marijuana prohibition consumes disproportionate law enforcement resources relative to public safety benefits. Raney noted that marijuana arrests require the same processing and documentation as violent crime arrests, diverting officer time from higher-priority activities.

What's Next: Timeline and Decision Points

The path from legislative approval to implementation involves multiple stages spanning 18-24 months, with several critical decision points that will determine whether Idaho implements medical marijuana. **June-December 2026: Signature Gathering Phase** Kind Idaho must collect approximately 63,000 valid signatures from registered Idaho voters, representing six percent of registered voters in at least 18 of Idaho's 35 legislative districts. The campaign has until December 31, 2026, to submit signatures to the Idaho Secretary of State. Based on historical validation rates, the campaign will likely aim to collect 100,000-110,000 raw signatures to ensure sufficient valid signatures after verification. The signature-gathering effort will focus on high-traffic locations including farmers markets, college campuses, and community events. Kind Idaho has budgeted $1.8 million for paid signature gatherers, who typically collect 60-70% of signatures in successful campaigns. The organization plans to deploy 150-200 paid gatherers statewide, supplemented by volunteer efforts. **January-March 2027: Signature Verification** The Idaho Secretary of State's office will verify submitted signatures against voter registration records, a process that typically takes 60-90 days. This verification phase proved contentious in 2024, when the Secretary of State invalidated 31% of submitted signatures. Kind Idaho has hired election law attorneys to monitor the verification process and ensure consistent application of validation standards. If the Secretary of State certifies sufficient valid signatures, the measures will qualify for the November 2027 general election ballot. If signature counts fall short, Kind Idaho could file legal challenges, though courts have historically deferred to the Secretary of State's verification authority. **April-November 2027: Campaign Phase** Once ballot qualification is certified, both supporters and opponents will launch full-scale campaigns. Kind Idaho has set a $3.5 million fundraising goal for the campaign phase, while opposition groups including the Idaho Sheriffs' Association are expected to raise $2-3 million. The campaign will likely focus on patient testimonials, economic benefits, and criminal justice reform arguments, while opponents will emphasize youth protection, impaired driving, and federal law conflicts. Polling will be critical during this phase. The University of Idaho's most recent poll (March 2026) showed 61% support for medical marijuana, but ballot measure support often declines as opposition campaigns raise concerns. Campaigns typically need 55-60% support in early polling to maintain majority support through election day. **November 2027: Election Day** Idaho voters will decide on both the constitutional amendment and statutory initiative. Both measures must pass for implementation to proceed—the constitutional amendment removes the prohibition barrier, while the statutory initiative establishes the regulatory framework. This two-measure approach creates vulnerability, as opponents need only defeat one measure to block reform. Historical data from other states suggests medical marijuana ballot measures pass with 55-65% support in conservative states. Montana's 2020 measure passed with 57% approval, while Utah's 2018 measure received 53%. Idaho's success will likely depend on turnout patterns, as younger voters and Democrats show stronger support while older voters and Republicans remain more skeptical. **December 2027-June 2028: Regulatory Development** If voters approve both measures, the Idaho Department of Health and Welfare and Idaho State Police would begin developing implementing regulations. This process typically takes 6-9 months and includes: - Establishing the patient registry system and identification card application process - Developing cultivation, processing, and dispensary licensing frameworks - Creating testing standards and laboratory certification requirements - Drafting packaging, labeling, and advertising regulations - Establishing enforcement protocols and compliance inspection procedures The regulatory development phase will involve public comment periods and stakeholder input. Industry groups, patient advocates, and law enforcement will all seek to influence regulatory details that can significantly impact market structure and access. **July 2028-January 2029: License Applications and Awards** Idaho would likely accept cultivation, processing, and dispensary license applications in summer 2028, with initial awards in fall 2028. The application process will be competitive, particularly for dispensary licenses in desirable locations. Applicants will need to demonstrate financial capacity, security plans, and compliance expertise. License application fees will likely total $50,000-100,000 per license type, based on comparable state frameworks. This creates barriers to entry that favor well-capitalized applicants, potentially including multi-state operators despite any residency preferences. **January-June 2029: Market Launch** The first Idaho medical marijuana dispensaries would likely open in early 2029, approximately 18 months after voter approval. Initial supply constraints are common in new markets as cultivation facilities ramp up production. Idaho regulators may authorize temporary imports from neighboring states to ensure adequate supply, as Utah did during its market launch. Patient registration would begin simultaneously with market launch. Idaho will likely see 10,000-15,000 patient applications in the first three months, based on pent-up demand from patients currently traveling to neighboring states or operating in the illegal market.

Further Reading and Primary Sources

• Idaho Code § 37-2701 et seq., Idaho Uniform Controlled Substances Act - Full text of Idaho's current cannabis prohibition statutes: https://legislature.idaho.gov/statutesrules/idstat/Title37/T37CH27/
• Idaho Constitution, Article III, Section 26 - Constitutional provision prohibiting substances on federal controlled substances schedules: https://legislature.idaho.gov/statutesrules/idconst/ArtIII/Sect26/
• 21 U.S.C. § 812, Controlled Substances Act schedules - Federal drug scheduling framework: https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm
• Kind Idaho official campaign website - Ballot measure language, patient testimonials, and campaign updates: https://kindidaho.org
• Idaho Secretary of State Elections Division - Official ballot measure status and signature verification: https://sos.idaho.gov/elections-division/
• Idaho State Police HIDTA program annual report - Cannabis seizure data and interdiction statistics: https://isp.idaho.gov/
• University of Idaho public opinion polling on cannabis policy - Periodic surveys of Idaho voter attitudes: https://www.uidaho.edu/news/polls
• Montana Cannabis Control Division - Comparable medical program regulatory framework: https://mtrevenue.gov/cannabis/
• Utah Department of Health and Human Services Medical Cannabis Program - Another conservative-state medical program model: https://medicalcannabis.utah.gov/
• DEA Notice of Proposed Rulemaking on cannabis rescheduling - Federal Register docket for Schedule III rescheduling proposal: https://www.federalregister.gov/
• Idaho Sheriffs' Association policy positions - Law enforcement perspective on cannabis policy: https://idahosheriffs.org/
• Whitney Economics Idaho market analysis - Economic projections for potential Idaho medical marijuana market: https://whitneyeconomics.com/